Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

• Robert Landewé,
• Désirée van der Heijde,
• Atul Deodhar,
• Martin Rudwaleit,
• Lianne S Gensler,
• Walter P Maksymowych,
• Bengt Hoepken,
• Lars Bauer,
• Thomas Kumke,
• Mindy Kim,
• Simone Emanuele Auteri

Affiliations

Robert Landewé

Rheumatology Department, Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands

Désirée van der Heijde

Rheumatology Department, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands

Atul Deodhar

3 Oregon Health & Science University, Portland, Oregon, USA

Martin Rudwaleit

Department of Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany

Lianne S Gensler

32 Division of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA

Walter P Maksymowych

1 Medicine, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada

Bengt Hoepken

8 UCB Pharma, Monheim am Rhein, Germany

Lars Bauer

8 UCB Pharma, Monheim am Rhein, Germany

Thomas Kumke

UCB Pharma, Monheim am Rhein, Germany

Mindy Kim

UCB Pharma, Smyrna, Georgia, USA

Simone Emanuele Auteri

UCB Pharma, Milan, Italy